Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -0.17% | 170.82 | 0.7% | $967.58m | |
| ABBV | AbbVie, Inc. | 1.33% | 139.88 | 1.9% | $839.03m | |
| PFE | Pfizer Inc. | 0.32% | 49.43 | 0.9% | $827.77m | |
| LLY | Eli Lilly & Co. | -0.23% | 300.63 | 1.1% | $744.48m | |
| MRK | Merck & Co., Inc. | 0.21% | 87.59 | 0.7% | $741.41m | |
| BMY | Bristol-Myers Squibb Co. | 0.68% | 72.61 | 1.0% | $654.24m | |
| SIGA | SIGA Technologies, Inc. | -4.94% | 22.15 | 0.0% | $392.48m | |
| AZN | AstraZeneca Plc | -0.59% | 65.64 | 1.0% | $379.22m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 4.76% | 228.99 | 8.1% | $252.76m | |
| GSK | GSK Plc | -0.20% | 40.49 | 0.3% | $217.43m | |
| HZNP | Horizon Therapeutics Plc | 1.48% | 70.63 | 5.4% | $200.72m | |
| SGEN | Seagen Inc. | 2.06% | 179.43 | 5.7% | $192.63m | |
| NVS | Novartis AG | 0.69% | 86.16 | 0.2% | $174.58m | |
| RGEN | Repligen Corp. | 0.77% | 248.17 | 6.7% | $156.95m | |
| NVO | Novo Nordisk A/S | -0.29% | 102.90 | 0.1% | $152.45m |
Company Profile
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.